Implementation of a reformulated Roche® bilirubin Gen.3 reagent did not affect the relationship between BiliChek transcutaneous and Roche total serum bilirubin-Reference-Cited by-同舟云学术

Implementation of a reformulated Roche® bilirubin Gen.3 reagent did not affect the relationship between BiliChek transcutaneous and Roche total serum bilirubin

Published:2019-01 Issue: Volume:63 Page:148-151
ISSN:0009-9120
Container-title:Clinical Biochemistry
language:en
Short-container-title:Clinical Biochemistry

Author:

Jara Aguirre Jose C.,Wockenfus Amy M.,Krekelberg Benjamin J.,Fine Kara L.,Cook Walter J.,Karon Brad S.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,General Medicine

Reference16 articles.

1. Neonatal hyperbilirubinemia;Dennery;N. Engl. J. Med.,2001

2. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications;Maisels;Pediatrics,2009

3. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) – Summary

4. Better Outcomes through Research for Newborns Network. Discrepancies between transcutaneous and serum bilirubin measurements;Taylor;Pediatrics,2015

5. A comparison of transcutaneous and total serum bilirubin in newborn Hispanic infants at 35 or more weeks of gestation;Kolman;J. Am. Board Fam. Med.,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accuracy and Reproducibility of BiliCare™ Transcutaneous Bilirubin Device;Clinical Laboratory;2023

2. Refining interpretation of transcutaneous bilirubin measurement in newborns born late preterm;Pediatrics & Neonatology;2022-09

3. Error simulation modeling to assess the effects of bias and precision on bilirubin measurements used to screen for neonatal hyperbilirubinemia;Clinical Chemistry and Laboratory Medicine (CCLM);2021-01-20